About: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 1993 (uk) im Jahr 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 1993 (ast) artikull shkencor i botuar më 01 janar 1993 (sq) scientific article published on 01 January 1993 (en)
publication date	wds:Q72358571-ED35A513-E31E-4E8E-8157-2A7EA1F43566
publication date	1993-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q72358571-271065B1-7F85-4EE3-BCA0-CD35C2B74C6A wds:Q72358571-9020A2E2-61B3-488D-89A3-12B04883A879 wds:Q72358571-A18B67B7-406C-4D8D-A391-E308B1FCCFAF wds:Q72358571-A58AFC44-DD1C-4DE3-AA38-30AD8D9D18AB wds:Q72358571-BCB1C471-803B-4956-9D23-2D993224CE7B wds:Q72358571-C3939DD7-15BB-429D-BA11-AEF63FF0D994 wds:Q72358571-C734DD69-93A5-44C6-86D9-499C807EDB46 wds:Q72358571-CFB1A07E-FB7D-4FD4-9A74-185DB9856E1B wds:Q72358571-F6648109-DBE3-467A-A292-D1C4A9AB9A0F
author name string	M R Bishop J G Sharp G Zon A Kessinger E Bayever S J Pirruccello R W Ruddon M A Arneson H K Tewary
rdfs:label	Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (en) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (nl) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (sq)
skos:prefLabel	Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (en) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (nl) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (sq)
name	Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (en) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (nl) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (sq)
author	wds:Q72358571-7F1A5475-A845-4A84-BB90-1B85302497AD
author	Patrick L Iversen
title	wds:Q72358571-075AF93C-538B-47F6-9B57-91EB9CB618CF
title	Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial (en)
page(s)	wds:Q72358571-0A27CB86-CFFB-4EA3-BB1D-056C7C936343
page(s)	383-390
instance of	wds:Q72358571-F572EDB7-6FCD-4B49-966A-0F0D76EAC099
instance of	scholarly article
main subject	wds:Q72358571-7DE65190-7478-401A-90C2-FD2C3BB1B050 wds:Q72358571-AC528F66-0436-40F5-B889-96622A3D34CB
main subject	phase I clinical trial myelodysplastic syndrome
PubMed ID	wds:Q72358571-8F3F8C10-C50C-4A1F-8ADC-D86D94C74364
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8155979
PubMed ID	8155979
published in	wds:Q72358571-9FB95884-FFF3-4B0C-80CF-F340AE018637
published in	Antisense research and development
issue	wds:Q72358571-BA3159EE-79BE-46B7-B89C-527F8DD17C2F
volume	wds:Q72358571-7554CFB0-6DE6-4E59-8147-B8F28A748D3F
issue	4
volume	3
DOI	wds:Q72358571-7338BB4E-FE72-4701-8B14-077B39B791EC
DOI	http://dx.doi.org/10.1089/ARD.1993.3.383
DOI	10.1089/ARD.1993.3.383
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72358571
is cites work of	Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Gene inhibition using antisense oligodeoxynucleotides Effects of synthetic oligonucleotides on human complement and coagulation Synthetic oligonucleotides as therapeutics: the coming of age. Pharmacokinetics of antisense oligonucleotides Progress in antisense technology: the end of the beginning CpG motifs in bacterial DNA trigger direct B-cell activation Oligonucleotide Therapies: The Past and the Present Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides Oligonucleotide N3'-->P5' phosphoramidates as antisense agents Single strand targeted triplex-formation. Destabilization of guanine quadruplex structures by foldback triplex-forming oligonucleotides Antisense cancer therapy: the state of the science Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity An oligodeoxyribonucleotide N3'--> P5' phosphoramidate duplex forms an A-type helix in solution Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A. Sequence identity of the n-1 product of a synthetic oligonucleotide Investigation of the 'n-1' impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase beta-cyanoethyl phosphoramidite method using stepwise sulfurization Gene therapy strategies for leukemia Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12.[d/r(GT/U)]12 and the influence of phosphorothioate substitution Eliciting the low-activity aldehyde dehydrogenase Asian phenotype by an antisense mechanism results in an aversion to ethanol Sequencing of synthetic oligonucleotides and analogs by homopolymeric tailing [Contribution of antineoplastic biotherapy in the treatment of leukemia in children] Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors Inhibition of gene expression by anti-sense oligodeoxynucleotides Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software